Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach
暂无分享,去创建一个
[1] T. Terasaki,et al. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. , 2013, Journal of pharmaceutical sciences.
[2] S-M Huang,et al. Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence‐Based Position , 2013, Clinical pharmacology and therapeutics.
[3] H. Sugimoto,et al. Retrospective Analysis of P-Glycoprotein–Mediated Drug-Drug Interactions at the Blood-Brain Barrier in Humans , 2013, Drug Metabolism and Disposition.
[4] E. D. Lange. Utility of CSF in translational neuroscience , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[5] F. Theil,et al. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. , 2013, Molecular pharmaceutics.
[6] K. Pang,et al. Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.
[7] R. Shawahna,et al. Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. , 2012, Current drug metabolism.
[8] W. Jusko,et al. Applications of minimal physiologically-based pharmacokinetic models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[9] B. Walther,et al. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. , 2012, Journal of pharmaceutical sciences.
[10] A. Doran,et al. An Evaluation of Using Rat-Derived Single-Dose Neuropharmacokinetic Parameters to Project Accurately Large Animal Unbound Brain Drug Concentrations , 2012, Drug Metabolism and Disposition.
[11] A. Gupta,et al. In vivo microdialysis in pharmacological studies of antibacterial agents in the brain. , 2012, British journal of anaesthesia.
[12] A. Palmer,et al. Translational CNS medicines research. , 2012, Drug discovery today.
[13] R. Stratford,et al. Microdialysis Evaluation of Clozapine and N-Desmethylclozapine Pharmacokinetics in Rat Brain , 2012, Drug Metabolism and Disposition.
[14] Á. Kittel,et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[15] Aleksandra Galetin,et al. Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.
[16] A. Rostami-Hodjegan,et al. Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.
[17] Bart Ploeger,et al. Physiologically Based Pharmacokinetic Modeling to Investigate Regional Brain Distribution Kinetics in Rats , 2012, The AAPS Journal.
[18] R. Stratford,et al. Exploratory Translational Modeling Approach in Drug Development to Predict Human Brain Pharmacokinetics and Pharmacologically Relevant Clinical Doses , 2012, Drug Metabolism and Disposition.
[19] E. Sands,et al. Cerebrospinal Fluid Can Be Used as a Surrogate to Assess Brain Exposures of Breast Cancer Resistance Protein and P-Glycoprotein Substrates , 2012, Drug Metabolism and Disposition.
[20] E. Kis,et al. Efflux transporters in the blood–brain interfaces – in vitro and in vivo methods and correlations , 2012, Expert opinion on drug metabolism & toxicology.
[21] François Bouzom,et al. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? , 2012, Biopharmaceutics & drug disposition.
[22] R. Voskuyl,et al. Alteration in P-glycoprotein Functionality Affects Intrabrain Distribution of Quinidine More Than Brain Entry—A Study in Rats Subjected to Status Epilepticus by Kainate , 2012, The AAPS Journal.
[23] Yuichi Sugiyama,et al. Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate , 2011, Journal of Pharmacology and Experimental Therapeutics.
[24] T. Terasaki,et al. Blood-Brain Barrier (BBB) Pharmacoproteomics: Reconstruction of In Vivo Brain Distribution of 11 P-Glycoprotein Substrates Based on the BBB Transporter Protein Concentration, In Vitro Intrinsic Transport Activity, and Unbound Fraction in Plasma and Brain in Mice , 2011, Journal of Pharmacology and Experimental Therapeutics.
[25] T. Terasaki,et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. , 2011, Journal of pharmaceutical sciences.
[26] M. Danhof,et al. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. , 2011, Journal of pharmaceutical sciences.
[27] T. Terasaki,et al. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. , 2011, Journal of pharmaceutical sciences.
[28] Ignacio A. Romero,et al. Development of a three-dimensional, all-human in vitro model of the blood–brain barrier using mono-, co-, and tri-cultivation Transwell models , 2011, Journal of Neuroscience Methods.
[29] I. Wilhelm,et al. Quinidine as an ABCB1 Probe for Testing Drug Interactions at the Blood–Brain Barrier , 2011, Journal of biomolecular screening.
[30] C. Daumas-Duport,et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. , 2011, Molecular pharmaceutics.
[31] D. Scott,et al. Species Independence in Brain Tissue Binding Using Brain Homogenates , 2011, Drug Metabolism and Disposition.
[32] A. Avdeef. How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood-brain barrier permeability? , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[33] Jos H Beijnen,et al. Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics , 2011, Drug Metabolism and Disposition.
[34] Alain Pruvost,et al. In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery. , 2011, Molecular pharmaceutics.
[35] Takashi Suzuki,et al. Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.
[36] Ulf Bredberg,et al. Measurement of Unbound Drug Exposure in Brain: Modeling of pH Partitioning Explains Diverging Results between the Brain Slice and Brain Homogenate Methods , 2011, Drug Metabolism and Disposition.
[37] L. Helmdach,et al. Brain Tissue Binding of Drugs: Evaluation and Validation of Solid Supported Porcine Brain Membrane Vesicles (TRANSIL) as a Novel High-Throughput Method , 2011, Drug Metabolism and Disposition.
[38] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[39] A. Avdeef,et al. Physicochemical Selectivity of the BBB Microenvironment Governing Passive Diffusion—Matching with a Porcine Brain Lipid Extract Artificial Membrane Permeability Model , 2011, Pharmaceutical Research.
[40] Michael L Shuler,et al. Murine in vitro model of the blood-brain barrier for evaluating drug transport. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[41] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[42] Sagar Agarwal,et al. The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.
[43] J. Hakkarainen,et al. Comparison of in vitro cell models in predicting in vivo brain entry of drugs. , 2010, International journal of pharmaceutics.
[44] Edward H. Kerns,et al. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.
[45] Stina Syvänen,et al. Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. , 2010, Current topics in medicinal chemistry.
[46] Sagar Agarwal,et al. Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux , 2010, Journal of Pharmacology and Experimental Therapeutics.
[47] H. Kusuhara,et al. Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone , 2010, Journal of Pharmacology and Experimental Therapeutics.
[48] Santiago Vilar,et al. Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. , 2010, Journal of molecular graphics & modelling.
[49] Alex Avdeef,et al. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? , 2010, Journal of medicinal chemistry.
[50] Jeih-San Liow,et al. P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-Loperamide , 2010, Journal of Nuclear Medicine.
[51] Y. Sugiyama,et al. Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates , 2010, Pharmaceutical Research.
[52] David J. Begley,et al. Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.
[53] P. Jeffrey,et al. Assessment of the blood–brain barrier in CNS drug discovery , 2010, Neurobiology of Disease.
[54] Alex Avdeef,et al. Leakiness and Size Exclusion of Paracellular Channels in Cultured Epithelial Cell Monolayers–Interlaboratory Comparison , 2010, Pharmaceutical Research.
[55] Jun Li,et al. Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis , 2009, Journal of Pharmacokinetics and Pharmacodynamics.
[56] Susanne Winiwarter,et al. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. , 2009, Journal of medicinal chemistry.
[57] Dominique Tytgat,et al. Physiologically based pharmacokinetics (PBPK) , 2009, Drug metabolism reviews.
[58] Li Di,et al. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. , 2009, Journal of pharmaceutical sciences.
[59] Ulf Bredberg,et al. Development of a High-Throughput Brain Slice Method for Studying Drug Distribution in the Central Nervous System , 2009, Drug Metabolism and Disposition.
[60] Jeih-San Liow,et al. Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein , 2009, Journal of Nuclear Medicine.
[61] M. Monshouwer,et al. Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid , 2009, Drug Metabolism and Disposition.
[62] Jos H. Beijnen,et al. Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment , 2009, Clinical Cancer Research.
[63] B. Långström,et al. Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.
[64] Joseph W. Polli,et al. An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.
[65] J. Schellens,et al. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib , 2009, Investigational New Drugs.
[66] Jun Yu Li,et al. Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination , 2009, Theoretical Biology and Medical Modelling.
[67] J. C. Kalvass,et al. Microdialysis Evaluation of Atomoxetine Brain Penetration and Central Nervous System Pharmacokinetics in Rats , 2009, Drug Metabolism and Disposition.
[68] S. Krähenbühl,et al. The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies , 2008, Journal of neurochemistry.
[69] R N Gunn,et al. Toward an improved prediction of human in vivo brain penetration , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[70] T. Terasaki,et al. Involvement of the Pyrilamine Transporter, a Putative Organic Cation Transporter, in Blood-Brain Barrier Transport of Oxycodone , 2008, Drug Metabolism and Disposition.
[71] Jeih-San Liow,et al. 11C-Loperamide and Its N-Desmethyl Radiometabolite Are Avid Substrates for Brain Permeability-Glycoprotein Efflux , 2008, Journal of Nuclear Medicine.
[72] Jashvant D Unadkat,et al. In Vitro-to-in Vivo Prediction of P-glycoprotein-Based Drug Interactions at the Human and Rodent Blood-Brain Barrier , 2008, Drug Metabolism and Disposition.
[73] Margareta Hammarlund-Udenaes,et al. Blood–Brain Barrier Transport Helps to Explain Discrepancies in In Vivo Potency between Oxycodone and Morphine , 2008, Anesthesiology.
[74] Bo Feng,et al. In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.
[75] Tetsuya Terasaki,et al. Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.
[76] Stina Syvänen,et al. On The Rate and Extent of Drug Delivery to the Brain , 2007, Pharmaceutical Research.
[77] U. Bredberg,et al. In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids , 2007, Drug Metabolism and Disposition.
[78] Anders Tunek,et al. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. , 2007, Journal of medicinal chemistry.
[79] M. Danhof,et al. Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat , 2007, Pharmaceutical Research.
[80] P. Jeffrey,et al. Challenges for blood–brain barrier (BBB) screening , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[81] Maxime Culot,et al. Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.
[82] Phil Jeffrey,et al. Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.
[83] T. Terasaki,et al. A functional in vitro model of rat blood–brain barrier for molecular analysis of efflux transporters , 2007, Brain Research.
[84] H. Koepsell,et al. Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.
[85] Kjell Johnson,et al. Porcine Brain Microvessel Endothelial Cells as an in Vitro Model to Predict in Vivo Blood-Brain Barrier Permeability , 2006, Drug Metabolism and Disposition.
[86] U. Simonsson,et al. In Vivo Blood-Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/Pharmacodynamics , 2006, Drug Metabolism and Disposition.
[87] J. Cianfrogna,et al. Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration , 2006, Drug Metabolism and Disposition.
[88] Xingrong Liu,et al. EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION , 2006, Drug Metabolism and Disposition.
[89] Mark Muzi,et al. Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data , 2006, Journal of Pharmacology and Experimental Therapeutics.
[90] J. Scherrmann,et al. Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide. , 2006, Life sciences.
[91] Phil Jeffrey,et al. Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.
[92] Andreas Reichel,et al. The role of blood-brain barrier studies in the pharmaceutical industry. , 2006, Current drug metabolism.
[93] E. D. Lange,et al. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling , 2005, The AAPS Journal.
[94] A. Palmer,et al. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery , 2005, NeuroRx.
[95] K. Bernard,et al. NEUROPHARMACOKINETICS OF A NEW α-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC ACID (AMPA) MODULATOR, S18986 [(S)-2,3-DIHYDRO-[3,4]CYCLOPENTANO-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE], IN THE RAT , 2005, Drug Metabolism and Disposition.
[96] D. Mankoff,et al. Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.
[97] Ernesto Callegari,et al. Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding , 2005, Journal of Pharmacology and Experimental Therapeutics.
[98] Per Artursson,et al. Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method , 2005 .
[99] Danny D Shen,et al. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. , 2004, Advanced drug delivery reviews.
[100] E. Niclas Jonsson,et al. An Integrated Model for the Analysis of Pharmacokinetic Data from Microdialysis Experiments , 2004, Pharmaceutical Research.
[101] D. Hallifax,et al. Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and mdr1a(-/-) Mice in Vivo , 2004, Pharmaceutical Research.
[102] W. Pardridge,et al. Log(BB), PS products and in silico models of drug brain penetration. , 2004, Drug discovery today.
[103] Malcolm Rowland,et al. Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.
[104] Emi Nakashima,et al. New approaches to in vitro models of blood-brain barrier drug transport. , 2003, Drug discovery today.
[105] Li Di,et al. High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.
[106] Gordon L. Amidon,et al. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.
[107] D. Scott,et al. Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. , 2002, Journal of pharmaceutical and biomedical analysis.
[108] M. R. Bouw,et al. Blood‐brain barrier transport and brain distribution of morphine‐6‐glucuronide in relation to the antinociceptive effect in rats – pharmacokinetic/pharmacodynamic modelling , 2001, British journal of pharmacology.
[109] J. Platts,et al. Correlation and prediction of a large blood-brain distribution data set--an LFER study. , 2001, European journal of medicinal chemistry.
[110] M. R. Bouw,et al. Modelling of the blood‐brain barrier transport of morphine‐3‐glucuronide studied using microdialysis in the rat: involvement of probenecid‐sensitive transport , 2000, British journal of pharmacology.
[111] M. R. Bouw,et al. Pharmacokinetic-Pharmacodynamic Modelling of Morphine Transport Across the Blood-Brain Barrier as a Cause of the Antinociceptive Effect Delay in Rats—A Microdialysis Study , 2000, Pharmaceutical Research.
[112] M. Feher,et al. A simple model for the prediction of blood-brain partitioning. , 2000, International journal of pharmaceutics.
[113] R. Sawchuk,et al. Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. , 1997, Journal of pharmaceutical sciences.
[114] Y. Sugiyama,et al. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. , 1997, Journal of Pharmacology and Experimental Therapeutics.
[115] Y. Sugiyama,et al. Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. , 1997, The Journal of pharmacology and experimental therapeutics.
[116] Malcolm Rowland,et al. Physiologically Based Pharmacokinetic Modeling of a Homologous Series of Barbiturates in the Rat: A Sensitivity Analysis , 1997, Journal of Pharmacokinetics and Biopharmaceutics.
[117] Y. Sugiyama,et al. Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system☆ , 1997 .
[118] L. Paalzow,et al. Drug Equilibration Across the Blood—Brain Barrier-Pharmacokinetic Considerations Based on the Microdialysis Method , 1997, Pharmaceutical Research.
[119] Yanfeng Wang,et al. The Simultaneous Estimation of the Influx and Efflux Blood-Brain Barrier Permeabilities of Gabapentin Using a Microdialysis-Pharmacokinetic Approach , 1996, Pharmaceutical Research.
[120] R. Sawchuk,et al. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. , 1995, Journal of pharmaceutical sciences.
[121] W. Pardridge,et al. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. , 1990, The Journal of pharmacology and experimental therapeutics.
[122] R. Dedrick,et al. Distributed model for drug delivery to CSF and brain tissue. , 1983, The American journal of physiology.
[123] K. Pettigrew,et al. Drug entry into the brain , 1979, Brain Research.
[124] K D Pettigrew,et al. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.
[125] C. Patlak,et al. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. , 1977, Cancer treatment reports.
[126] J. Ghersi-Egea,et al. In Vitro Models of the Blood–Cerebrospinal Fluid Barrier and Their Use in Neurotoxicological Research , 2011 .
[127] H. Boriss. Brain Availability Is the Key Parameter for Optimising the Permeability of Central Nervous System Drugs , 2010 .
[128] A. Brancale,et al. Homology Modelling of Human E1 Ubiquitin Activating Enzyme. , 2010, Letters in drug design & discovery.
[129] M. Jamei,et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.
[130] F. Nelson,et al. The Effect of Breast Cancer Resistance Protein ( Bcrp ) and P-glycoprotein ( Mdr 1 a / 1 b ) on the Brain Penetration of Flavopiridol , Gleevec , Prazosin and PF-407288 in Mice , 2009 .
[131] Jiunn H. Lin,et al. CSF as a surrogate for assessing CNS exposure: an industrial perspective. , 2008, Current drug metabolism.
[132] P. Artursson,et al. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[133] Meihua Tu,et al. Development of a computational approach to predict blood-brain barrier permeability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[134] Y. Deguchi. Application of in vivo brain microdialysis to the study of blood-brain barrier transport of drugs. , 2002, Drug metabolism and pharmacokinetics.
[135] Meindert Danhof,et al. Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting , 2002, Clinical pharmacokinetics.
[136] Thomas J. Raub,et al. In vitro models for the blood-brain barrier. , 1998, Toxicology in vitro : an international journal published in association with BIBRA.
[137] C S Patlak,et al. Methods for Quantifying the transport of drugs across brain barrier systems. , 1981, Pharmacology & therapeutics.